Top

Published in:

01-08-2010 | Preclinical study

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

Authors: Ianko D. Iankov, Pavlos Msaouel, Cory Allen, Mark J. Federspiel, Peggy A. Bulur, Allan B. Dietz, Dennis Gastineau, Yasuhiro Ikeda, James N. Ingle, Stephen J. Russell, Evanthia Galanis

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 10⁶ plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80% compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

Available only for authorised users

Light RW (2002) Clinical practice. Pleural effusion. N Engl J Med 346(25):1971–1977

DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ (1997) Malignant effusive disease of the pleura and pericardium. Chest 112(Suppl 4):291S–295SCrossRefPubMed

Neragi-Miandoab S (2006) Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54(1):1–9CrossRefPubMed

Heffner JE, Klein JS (2008) Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 83(2):235–250CrossRefPubMed

Griffin D (2001) Measles virus. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 1401–1441

Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97(12):3746–3754CrossRefPubMed

Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ (2001) Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98(7):2002–2007CrossRefPubMed

Peng KW, Facteau S, Wegman T, O’Kane D, Russell SJ (2002) Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8(5):527–531CrossRefPubMed

Phuong LK, Allen C, Peng KW et al (2003) Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63(10):2462–2469PubMed

10.

Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E (2009) Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther 17(8):1395–1403CrossRefPubMed

11.

Msaouel P, Iankov ID, Allen C et al (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82–91CrossRefPubMed

12.

Yanagi Y, Takeda M, Ohno S (2006) Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 87:2767–2779

13.

McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E (2006) A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 99(2):177–184CrossRefPubMed

14.

Anderson BD, Nakamura T, Russell SJ, Peng KW (2004) High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64(14):4919–4926CrossRefPubMed

15.

Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R (2005) Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106(7):2287–2294CrossRefPubMed

16.

Iankov ID, Blechacz B, Liu C et al (2007) Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15(1):114–122CrossRefPubMed

17.

Demaison C, Parsley K, Brouns G et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13(7):803–813CrossRefPubMed

18.

Noser JA, Towers GJ, Sakuma R et al (2006) Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 80(15):7769–7774CrossRefPubMed

19.

Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK (1999) Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 73(11):9568–9575PubMed

20.

Duprex WP, McQuaid S, Roscic-Mrkic B, Cattaneo R, McCallister C, Rima BK (2000) In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 74(17):7972–7979CrossRefPubMed

21.

Dietz AB, Bulur PA, Emery RL et al (2006) A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 46(12):2083–2089CrossRefPubMed

22.

Dietz AB, Bulur PA, Knutson GJ, Matasic R, Vuk-Pavlovic S (2000) Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun 275(3):731–738CrossRefPubMed

23.

Haralambieva IH, Ovsyannikova IG, Vierkant RA, Poland GA (2008) Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity. Clin Vaccine Immunol 15(7):1054–1059CrossRefPubMed

24.

Chen RT, Markowitz LE, Albrecht P et al (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162(5):1036–1042PubMed

25.

Ward BJ, Aouchiche S, Martel N et al (1999) Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diagn Microbiol Infect Dis 33(3):147–152CrossRefPubMed

26.

Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY (2008) Genes controlling spread of breast cancer to lung “gang of 4”. Exp Oncol 30(2):91–95PubMed

27.

Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213–241CrossRefPubMed

28.

Ren S, Terman DS, Bohach G et al (2004) Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 126(5):1529–1539CrossRefPubMed

29.

Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54(8):707–710CrossRefPubMed

30.

Bielsa S, Salud A, Martinez M et al (2008) Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 19(5):334–339CrossRefPubMed

31.

Crnjac A, Sok M, Kamenik M (2004) Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg 26(2):432–436CrossRefPubMed

32.

Psathakis K, Calderon-Osuna E, Romero-Romero B et al (2006) The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis. Eur Respir J 27(4):817–821CrossRefPubMed

Title: Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
Authors: Ianko D. Iankov
Pavlos Msaouel
Cory Allen
Mark J. Federspiel
Peggy A. Bulur
Allan B. Dietz
Dennis Gastineau
Yasuhiro Ikeda
James N. Ingle
Stephen J. Russell
Evanthia Galanis
Publication date: 01-08-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0602-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls

Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall

Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer

Obesity and weight change in relation to breast cancer survival

Methylenetetrahydrofolate reductase C677T polymorphism in breast cancer risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer